GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GRI GRI BIO INC

Market Closed 01-16 16:00:00 EST

0.2225

-0.0183

-7.60%

盘后0.2348

+0.0123+5.53%

19:49 EST

High0.2520	Low0.2200	Vol1.03M
Open0.2520	D1 Closing0.2408	Amplitude13.29%
Mkt Cap2.25M	Tradable Cap1.31M	Total Shares10.12M
T/O234.90K	T/O Rate17.53%	Tradable Shares5.87M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GRI","market":"US","secType":"STK","nameCN":"GRI BIO INC","latestPrice":0.2225,"timestamp":1768597200000,"preClose":0.2408,"halted":0,"volume":1029161,"hourTrading":{"tag":"盘后","latestPrice":0.2348,"preClose":0.2225,"latestTime":"19:49 EST","volume":69927,"amount":16117.6958,"timestamp":1768610993211},"delay":0,"floatShares":5871600,"shares":10121100,"eps":-16.2498,"marketStatus":"Market Closed","change":-0.0183,"latestTime":"01-16 16:00:00 EST","open":0.252,"high":0.252,"low":0.22,"amount":234900.34815611,"amplitude":0.13289,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-16.2498,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768899600000},"marketStatusCode":7,"symbolChange":{"newSymbol":"RDOG","executeDate":"2020-01-02"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.2408,"sharesOutstanding":1100000,"nav":47.93,"aum":52503274.57,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":0.244,"preClose":0.2408,"latestTime":"09:29 EST","volume":71526,"amount":16197.55479888,"timestamp":1768573762373},"postHourTrading":{"tag":"盘后","latestPrice":0.2348,"preClose":0.2225,"latestTime":"19:49 EST","volume":69927,"amount":16117.6958,"timestamp":1768610993211},"volumeRatio":0.41539977447802184},"requestUrl":"/m/hq/s/GRI/wiki","defaultTab":"wiki","newsList":[{"id":"2603996871","title":"Nasdaq Warns Gri Bio Over Stockholders’ Equity Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2603996871","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603996871?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:01","pubTimestamp":1768568485,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. recently received a notice from the Nasdaq Stock Market LLC that it has conditionally regained compliance with the Nasdaq Listing Rule 5550, which requires companies to maintain stockholders' equity of at least $2.5 million. The company had previously been notified of non-compliance based on its financial filings for the quarter ended September 30, 2025. However, if Gri Bio Inc. fails to meet this equity requirement in future reports, its shares may once again face the risk of delisting from the Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLb9LC9Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRI","BK4139"],"gpt_icon":0},{"id":"2603998945","title":"Gri Bio Inc. Held Special Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2603998945","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603998945?lang=en_us&edition=fundamental","pubTime":"2026-01-15 23:15","pubTimestamp":1768490148,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. held a special meeting of stockholders on January 15, 2026. Stockholders approved an amendment to the company's certificate of incorporation to authorize a reverse stock split of common stock at a ratio to be determined by the board of directors within a specified range. Stockholders also approved the option to postpone or adjourn the meeting if necessary to solicit additional proxies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 15, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL3NywLC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"2601868364","title":"GRI Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2601868364","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601868364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877228,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. has announced additional positive data from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis . The randomized, double-blind, placebo-controlled study enrolled 35 subjects and assessed safety, tolerability, pharmacokinetics, and pharmacodynamic activity over 12 weeks of once-daily oral administration. New immune profiling data from bronchoalveolar lavage fluid and peripheral blood mononuclear cells demonstrated inhibition of invariant natural killer T  cell activity and a shift towards an anti-fibrotic immune profile. These results confirm the disease-modifying mechanism of GRI-0621 and reinforce earlier findings related to fibrosis resolution, lung repair, and improved lung function. The results have already been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for in","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDL2ByP40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014039.USD","BK4139","SG9999014013.SGD","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","GRI","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","BK4588","BK4007","LU0314104364.USD","IE00B3QW5Z07.USD","BK4585","SG9999014021.USD","LU2095319765.USD"],"gpt_icon":0},{"id":"2601364845","title":"GRI Bio Announces Additional Positive Data From Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364845?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA36FB92:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","GRI"],"gpt_icon":0},{"id":"2601364844","title":"GRI Bio Inc: GRI-0621 Continues to Demonstrate a Compelling Profile, Combining Favorable Safety and Tolerability","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364844?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA36FB92:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GRI","BK4007","BK4139"],"gpt_icon":0},{"id":"2593143451","title":"SM launches free MSME sustainability learning program","url":"https://stock-news.laohu8.com/highlight/detail?id=2593143451","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593143451?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:32","pubTimestamp":1766449920,"startTime":"0","endTime":"0","summary":"PASAY CITY, Philippines, Dec. 23, 2025 /PRNewswire/ -- SM Investments Corporation , in partnership with the Global Reporting Initiative , has launched the inaugural e-learning bridge course on sustainability reporting for micro, small, and medium enterprises . The course was unveiled during a recently concluded training workshop for publicly listed companies  at SMX Aura in Taguig.The event, \"Empowering Sustainable Business and Supply Chains: Building Capabilities for Impactful Sustainability Practices Across the Value Chain,\" aimed to help PLCs understand the interoperability between GRI Standards and the emerging disclosure expectations of the International Sustainability Standards Board .\"It's not just about producing reports and documentation,\" said SM Investments Consultant and Head of Investor Relations and Sustainability Timothy Daniels. \"We want to deepen understanding beyond the stories and behind the data, to empower our colleagues in the industry and now our MSME partners to","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1880730/Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1880730/Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/sm-launches-free-msme-sustainability-learning-program-302648372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","SM","ISSB","BK4213","BK4139","BK4007"],"gpt_icon":0},{"id":"1152823313","title":"China Insurance Association Publishes \"Guidelines for Environmental, Social, and Governance Disclosure by Insurance Institutions: Interpretations and Case Studies\"","url":"https://stock-news.laohu8.com/highlight/detail?id=1152823313","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152823313?lang=en_us&edition=fundamental","pubTime":"2025-12-16 18:00","pubTimestamp":1765879248,"startTime":"0","endTime":"0","summary":"To thoroughly implement the decisions of the Communist Party of China Central Committee and the State Council on promoting green development and advancing the \"Five Key Areas of Finance,\" while...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ESG","BK4139","GRI"],"gpt_icon":0},{"id":"2591681861","title":"GRI Bio Announces Closing of $8.0 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2591681861","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591681861?lang=en_us&edition=fundamental","pubTime":"2025-12-13 05:05","pubTimestamp":1765573500,"startTime":"0","endTime":"0","summary":"LA JOLLA, CA, Dec.  12, 2025  (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell mo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/12/3204858/0/en/GRI-Bio-Announces-Closing-of-8-0-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GRI","BK4139"],"gpt_icon":0},{"id":"2590512656","title":"GRI Bio Announces Pricing of $8,000,000 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2590512656","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590512656?lang=en_us&edition=fundamental","pubTime":"2025-12-11 22:15","pubTimestamp":1765462500,"startTime":"0","endTime":"0","summary":"LA JOLLA, CA, Dec.  11, 2025  (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell mo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/11/3204000/0/en/GRI-Bio-Announces-Pricing-of-8-000-000-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4007","BK4139"],"gpt_icon":0},{"id":"2590255354","title":"BUZZ-GRI Bio jumps as experimental lung drug shows promise in mid-stage trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590255354","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590255354?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:26","pubTimestamp":1765401992,"startTime":"0","endTime":"0","summary":"BUZZ-GRI Bio jumps as experimental lung drug shows promise in mid-stage trial** Shares of drug developer GRI Bio GRI.O rise 18% to $1.43 in after-hours trading** Co says its experimental drug, GRI-0621, showed promising results in a mid-stage clinical trial for idiopathic pulmonary fibrosis ** IPF is a chronic lung disease with limited treatment options, co says** Nearly 40% of treated patients saw better lung capacity vs 80% decline on placebo — GRI** Trial enrolled 35 patients, most on existing IPF drugs; blood tests suggest reduced lung scarring — GRI** Including session's move, stock down ~91% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nL4N3XG1LN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"2590967558","title":"GRI Bio Announces Positive Topline Data From Its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“Ipf”)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590967558","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590967558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUABBCDZW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"2590553525","title":"GRI Bio Inc - No Safety Concerns Observed in Subjects Enrolled at 12 Weeks of Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2590553525","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590553525?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUABBCDZW:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","GRI"],"gpt_icon":0},{"id":"2590548553","title":"GRI Bio Inc: Phase 2a Study Met Its Secondary Endpoints and Demonstrated Improvement in Biomarkers of Collagen Turnover","url":"https://stock-news.laohu8.com/highlight/detail?id=2590548553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590548553?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUABBCDZW:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","GRI","BK4139"],"gpt_icon":0},{"id":"2590535265","title":"GRI Bio Inc: Phase 2a Study Also Met Exploratory Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2590535265","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590535265?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUABBCDZW:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRI","BK4007"],"gpt_icon":0},{"id":"2590355354","title":"GRI Bio Inc - Study Shows GRI-0621 Well Tolerated Over 12 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2590355354","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590355354?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400701,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251210:nTUABBCDZW:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRI","BK4007"],"gpt_icon":0},{"id":"2590473558","title":"GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)","url":"https://stock-news.laohu8.com/highlight/detail?id=2590473558","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590473558?lang=en_us&edition=fundamental","pubTime":"2025-12-11 05:05","pubTimestamp":1765400700,"startTime":"0","endTime":"0","summary":"Study met its primary endpoint demonstrating that GRI-0621 was well tolerated over 12 weeks of treatment, with no drug-related severe or serious adverse events and no increase in GI issues when used w","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/10/3203497/0/en/GRI-Bio-Announces-Positive-Topline-Data-from-its-Phase-2a-Study-in-Idiopathic-Pulmonary-Fibrosis-IPF.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","GRI","PK","BK4181","BK4139","FVC","BK4007"],"gpt_icon":0},{"id":"2589735322","title":"BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589735322","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589735322?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:14","pubTimestamp":1765199673,"startTime":"0","endTime":"0","summary":"BRIEF-GRI Bio Inc - Receives Topline Data From Phase 2A Trial For Idiopathic Pulmonary Fibrosis - SEC FilingDec 8  - GRI Bio Inc GRI.O:GRI BIO INC - RECEIVES TOPLINE DATA FROM PHASE 2A TRIAL FOR IDIOPATHIC PULMONARY FIBROSIS - SEC FILINGGRI BIO INC - TRIAL MEETS PRIMARY ENDPOINT & CERTAIN SECONDARY ENDPOINTS; GRI-0621 WELL TOLERATED - SEC FILINGGRI BIO INC - NO SAFETY OR TOLERABILITY CONCERNS IN GRI-0621 TREATED SUBJECTS - SEC FILINGSource text: [ID:n0001824293-25-000160]Further company coverage: GRI.O ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4139","BK4007"],"gpt_icon":0},{"id":"2589353113","title":"GRI Bio Inc - Trial Meets Primary Endpoint & Certain Secondary Endpoints; GRI-0621 Well Tolerated - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353113","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353113?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:13","pubTimestamp":1765199585,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nFWN3XE10C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GRI","BK4007"],"gpt_icon":0},{"id":"2589353535","title":"Gri Bio Reports Positive Phase 2a Results for GRI-0621 in Idiopathic Pulmonary Fibrosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353535","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353535?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:01","pubTimestamp":1765198912,"startTime":"0","endTime":"0","summary":"Gri Bio Inc. has announced topline results from its Phase 2a clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis . The study met its primary endpoint, demonstrating that GRI-0621 was well tolerated over a 12-week treatment period. Secondary endpoints showed improvements in serum biomarkers of collagen turnover, suggesting potential fibrosis resolution and alveolar basement membrane repair. No significant safety or tolerability concerns were observed. The trial enrolled 35 subjects, with 80% receiving background standard of care treatments. Placebo-adjusted changes in Forced Vital Capacity  were observed, with a higher proportion of GRI-0621-treated subjects experiencing FVC increases compared to placebo. Additional analyses of secondary and exploratory endpoints are ongoing. Results have already been presented in the company's announcement.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLp58Br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GRI","BK4007","BK4139"],"gpt_icon":0},{"id":"2589331429","title":"GRI Bio Is Maintained at Buy by Ascendiant Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2589331429","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589331429?lang=en_us&edition=fundamental","pubTime":"2025-12-08 18:35","pubTimestamp":1765190100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GRI/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 08, 2025 05:35 ET (10:35 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GRI","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vallon-pharma.com","stockEarnings":[{"period":"1week","weight":-0.0111},{"period":"1month","weight":-0.4694},{"period":"3month","weight":-0.8853},{"period":"6month","weight":-0.8777},{"period":"1year","weight":-0.9814},{"period":"ytd","weight":-0.0985}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California.","exchange":"NASDAQ","name":"GRI BIO INC","nameEN":"GRI BIO INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest GRI BIO INC(GRI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"GRI BIO INC,GRI,GRI BIO INC股票,GRI BIO INC股票老虎,GRI BIO INC股票老虎国际,GRI BIO INC行情,GRI BIO INC股票行情,GRI BIO INC股价,GRI BIO INC股市,GRI BIO INC股票价格,GRI BIO INC股票交易,GRI BIO INC股票购买,GRI BIO INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"GRI BIO INC(GRI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest GRI BIO INC(GRI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction